Sugi Predict

Sugi Predict / Compounds / SCHEMBL10242790

SCHEMBL10242790

SCHEMBL10242790

CC(C)(C)OC(=O)N1C[C@H]2C[C@H]2C1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.74
▸ USP2 O75604 1/20 0.48
▸ SMN1; SMN2 Q16637 1/20 0.48
▸ CHRM2 P08172 1/20 0.46
▸ CHRM1 P11229 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ JAK1 P23458 2/20 0.45
▸ JAK2 O60674 1/20 0.45
▸ HPGD P15428 1/20 0.45
▸ EPHX2 P34913 1/20 0.44
▸ GPR119 Q8TDV5 3/20 0.43
▸ KDM4E B2RXH2 1/20 0.43
▸ RECQL P46063 1/20 0.42
▸ EPHX1 P07099 1/20 0.42
▸ PREP P48147 1/20 0.42
▸ DDB1 Q16531 1/20 0.41
▸ CRBN Q96SW2 1/20 0.41
▸ NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4224986 1.00 NR1H2 (0.74) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL19456156 1.00 NR1H2 (0.74) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL25010845 1.00 NR1H2 (0.74) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL23326893 0.93 NR1H2 (0.66) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL27440647 0.90 NR1H2 (0.63) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL24718098 0.90 NR1H2 (0.63) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL24990169 0.90 NR1H2 (0.63) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL21561564 0.90 NR1H2 (0.63) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL24718097 0.90 NR1H2 (0.63) NR1H2USP2SMN1; SMN2CHRM2CHRM1
SCHEMBL17630406 0.90 NR1H2 (0.63) NR1H2USP2SMN1; SMN2CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117447520-A Benzo ring substituted pyrimidine compound and application thereof 广州利弗克医药科技有限公司 2024-01-26 — — CN disclosed
WO-2023150291-A2 HETEROCYCLIC COMPOUNDS AND METHODS OF USE SCHRÖDINGER, INC. (US) 2023-08-10 — — WO disclosed
WO-2023116734-A1 FUSED PYRROLIDINE COMPOUNDS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY VIRAL INFECTIONS SHANGHAI MICURX PHARMACEUTICAL CO., LTD. (CN) 2023-06-29 — — WO disclosed
EP-4119553-A1 COMPOUND USED AS KINASE INHIBITOR AND USE THEREOF TYK Medicines (Zhengzhou), Inc. (CN) 2023-01-18 — — EP disclosed
US-11154563-B2 Immunoproteasome inhibitors PRINCIPIA BIOPHARMA INC. (US) 2021-10-26 — — US disclosed
US-20190336515-A1 IMMUNOPROTEASOME INHIBITORS PRINCIPIA BIOPHARMA INC. 2019-11-07 — — US disclosed
WO-2018044808-A1 INHIBITORS OF DUAL LEUCINE ZIPER (DLK) KINASE FOR THE TREATMENT OF DISEASE BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) 2018-03-08 — — WO disclosed
US-9770439-B2 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2017-09-26 — — US disclosed
US-9751873-B2 Aryl sultam derivatives as RORc modulators GENENTECH, INC. (US) 2017-09-05 — — US disclosed
US-9751873-B2 Aryl sultam derivatives as RORc modulators GENENTECH, INC. (US) 2017-09-05 — — US disclosed
US-20160168141-A1 ARYL SULTAM DERIVATIVES AS RORc MODULATORS GENENTECH, INC. (US) 2016-06-16 — — US disclosed
WO-2014111496-A1 3-SUBSTITUTED PYRAZOLES AND USE AS DLK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-07-24 — — WO disclosed
US-8124639-B2 Bicyclic [3.1.0] heteroaryl amides as type 1 glycine transport inhibitors PFIZER INC. (US) 2012-02-28 — — US disclosed
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 — — US disclosed
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors PFIZER INC. 2010-12-23 — — US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 — — US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 — — US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 — — US disclosed
WO-2008023239-A1 PYRIMIDONE COMPOUNDS AS GSK-3 INHIBITORS PFIZER PRODUCTS INC. (US) 2008-02-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160168141-A1 ARYL SULTAM DERIVATIVES AS RORc MODULATORS RORC, RORB, RORA NR1H2 28/4885USP2 2603/4885SMN1; SMN2 3342/4885
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions CYP11B2, CYP11B1, LTC4S NR1H2 240/4885USP2 4676/4885SMN1; SMN2 1483/4885
US-20100324020-A1 Bicyclic [3.1.0] Heteroaryl Amides As Type 1 Glycine Transport Inhibitors SLC1A2, SLC1A1, SLC6A5 NR1H2 1193/4885USP2 4540/4885SMN1; SMN2 3737/4885
US-11154563-B2 Immunoproteasome inhibitors PSMC2, PSMB7, PSMB2 NR1H2 2768/4885USP2 84/4885SMN1; SMN2 1600/4885
US-20190336515-A1 IMMUNOPROTEASOME INHIBITORS PSMC2, PSMB7, PSMB2 NR1H2 2768/4885USP2 84/4885SMN1; SMN2 1600/4885
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions CYP11B2, CYP11B1, LTC4S NR1H2 240/4885USP2 4676/4885SMN1; SMN2 1483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.